Hannah Gordon, PhD, MSCI (@brieski) just made the Top 100 Women in AI list, and we couldn't be more proud!
As Enveda's Chief Scientific Officer, Hannah steers the pipeline, translating the chemical complexity of nature into a new generation of first-in-class medicines. She brings scientific depth and vision to deploy AI with one goal in mind: maximum impact for patients.
This list celebrates an exceptional cross-industry cohort of women defining the AI era, leading with purpose, and shaping the future.
Congratulations to all the honorees. Read more from XFactor Ventures and Flybridge here: https://t.co/XRbfkx4jdy
#100WomenInAI #WomenInAI #ArtificialIntelligence
We are about to again experience the covid like situation. Shops are getting closed and people are loosing jobs again. Please @PMOIndia consider this crisis as a real one. For god sake do not make policies just secure next term. @narendramodi
All the government just ignoring the power of a common man. They are cheking the patience. Remember public can drag you to the ground when ever they want. And that time come for @BJP4India and @narendramodi_in very soon.
What is happening in India is very is concerning. Any government, either the @INCIndia nor the @BJP4India care about the people, no body cared to have proper policy. All the government just worked to secure their next tenure in power.
I was very eager to try the udan yatri cafe in Bhubaneswar airport. But to my surprise I found that it was located before checkin and security, more towards arrival termimnal. How cleaverly they put it there. @AAI_Official
I was trying to book a flight recently. Then I saw the price breakdown. The ticket price is Rs. 10,000 and taxes are Rs. 3,000. It is almost 40% of the ticket price. @MoCA_GoI@RamMNK@IndiGo6E@EaseMyTrip
May be this is the perfect aaawwww timing for middle class. @nsitharaman
#JPM26 was the best yet for Enveda - presenting at a packed house at the conference, where we discussed our incredible 𝗣𝗵𝗮𝘀𝗲 𝟭𝗯 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗶𝗻 𝗮𝘁𝗼𝗽𝗶𝗰 𝗱𝗲𝗿𝗺𝗮𝘁𝗶𝘁𝗶𝘀, and building a 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗯𝗶𝗼𝘁𝗲𝗰𝗵.
We've been working hard behind the scenes to get us to where we are today, with 𝟰 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝘀 𝗶𝗻 𝗷𝘂𝘀𝘁 𝟲 𝘆𝗲𝗮𝗿𝘀 in the largest indications, and we are just getting started.
You might even have caught one of our ads for our 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 in 𝗮𝘁𝗼𝗽𝗶𝗰 𝗱𝗲𝗿𝗺𝗮𝘁𝗶𝘁𝗶𝘀 and 𝗼𝗯𝗲𝘀𝗶𝘁𝘆!
Patients need new and differentiated options and can't wait!
Stay tuned!
#JPMHC26
Six years ago, this was a thesis. Today, it’s clinical data.
Next week at #JPM26, we’ll be sharing progress that reflects years of deliberate choices coming together.
Our oral therapy for atopic dermatitis, ENV-294, has generated compelling Phase 1b data showing strong clinical activity and a clean safety profile in one of the largest and most competitive categories in medicine. The signal supports best-in-disease potential and represents exciting clinical proof of the thesis Enveda was built on.
ENV-294 matters not just because it is a strong program, but because it is the output of a system we have been building since day one. A company singularly focused on discovering, developing, and delivering breakthrough medicines with the potential to not just capture, but create markets.
We now have three assets in the clinic:
ENV-294 in atopic dermatitis and asthma, now in Phase 2a with a Jak-like efficacy and a Dupi-like safety profile
ENV-308 for obesity, with the first patient dosed in Phase 1, a “statin for obesity”, engineered for a post-GLP1 world
ENV-6946 for IBD, bringing together clinically validated biology across TNFa, TL1A, IL23, and NLRP3, via a single novel-target delivered in a convenient pill
With additional INDs expected in 2026, Enveda is now a multi-asset clinical-stage company with a highly concentrated set of upcoming catalysts.
Looking ahead over the next several quarters, this foundation provides both momentum and resilience. It positions us to move quickly, take meaningful swings, and continue building a generational company that endures.
We look forward to sharing more next week in San Francisco.
#JPM26 #ENV294 #ENV308 #DrugDiscovery #ClinicalTrials #Biotech #Enveda #LearningFromLife #RevolutionizingImmunology #RevolutionizingObesity
This is the kind of loot is happening in India. In stead of reducing price Britannia is giving 2 buiscuite extra. Giving two buiscuits extra actually cost nothing to the company. @nsitharaman@PMOIndia
@RajeshwariRW This is not 100% policies and government. Its the people and mentality and discipline of people which make China and any other country what they are currently.
@dstock_insights It is not always about the government and corruption, we as citizen also has some social responsibility. How many of us following or has civic rules in our daily lives. It is always very convenient to blame governments.